US 12,116,402 B2
Antibodies against clostridium difficile toxins and methods of using the same
Stephen F. Anderson, Arlington, MA (US); Natalie Anosova, Lexington, MA (US); Nicola Beltraminelli, Lyons (FR); Pierre Garrone, Lyons (FR); Harold Kleanthous, Chelmsford, MA (US); Majid Mehtali, Paris (FR); and Jianxin Zhang, Acton, MA (US)
Assigned to SANOFI PASTEUR INC., Swiftwater, PA (US)
Filed by SANOFI PASTEUR INC., Swiftwater, PA (US)
Filed on Nov. 30, 2021, as Appl. No. 17/538,731.
Application 17/538,731 is a division of application No. 16/204,624, filed on Nov. 29, 2018, granted, now 11,220,537.
Application 16/204,624 is a continuation of application No. 14/776,146, granted, now 10,160,797, issued on Dec. 25, 2018, previously published as PCT/US2014/028637, filed on Mar. 14, 2014.
Claims priority of provisional application 61/794,071, filed on Mar. 15, 2013.
Prior Publication US 2022/0089700 A1, Mar. 24, 2022
Int. Cl. A61K 39/40 (2006.01); C07K 16/12 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1282 (2013.01) [A61K 39/40 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 4 Claims
 
1. An isolated nucleic acid that encodes the amino acid sequence of one or more of the complementarity determining regions (CDRs) of a heavy chain variable domain and/or light chain variable domain of an isolated monoclonal antibody that binds to Clostridium difficile toxin A,
(a) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:2 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:4;
(b) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:20 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:22;
(c) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:38 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:40;
(d) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:56 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:58; or
(e) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:74 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:76; or
an isolated monoclonal antibody that binds to Clostridium difficile toxin B,
(a) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:92 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:94;
(b) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:110 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:112;
(c) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:128 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:130;
(d) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:146 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 148;
(e) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 164 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:166; or
(f) wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:182 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:184.